DrugDevelopment

Keros Therapeutics Faces Setback as Lung Drug Trial Dosing is Halted

11 days ago

In a significant blow to Keros Therapeutics, the company announced a temporary halt in dosing during a clinical trial for its experimental lung drug. This decision comes after preliminary safety concerns arose, leading to a rapid decline in the company’s stock value.

Malik's Bold Move: 1789 Capital Invests in Controversial Drug Startup BlinkRx

1 month ago

In a striking development within the pharmaceutical investment landscape, 1789 Capital, under the leadership of co-founder and activist investor Vivek Malik, has announced a significant investment in BlinkRx, a drug startup that is rapidly making waves for its unique business model and strong ideological stance. This partnership is not just about financial backing; it also exemplifies Malik's commitment to moving against the prevailing “woke” culture that he believes has stifled innovation and growth in the industry.

Halozyme Eyes Takeover Bid for Germany's Evotec: A New Era in Biotech Consolidation?

1 month ago

In a significant development in the global biotech landscape, Germany’s leading drug development firm, Evotec SE, has reportedly caught the attention of Halozyme Therapeutics Inc., an American company known for its innovative drug delivery technologies. This potential takeover could reshape the competitive dynamics within the industry, sparking speculation about future collaborations and growth trajectories.

AbbVie’s New Schizophrenia Drug Suffers Major Setback in Clinical Trials

1 month ago

AbbVie, the biopharmaceutical giant known for its innovative drug portfolio, has experienced a significant downturn following disappointing results from two large-scale clinical trials of its investigational drug for schizophrenia. This development has sent ripples through the pharmaceutical sector, resulting in a substantial drop in the company’s stock price.

Bristol Myers Squibb Boosts Forecast Thanks to Robust Demand for Eliquis and New Medications

2 months ago

Bristol Myers Squibb has recently announced plans to elevate its financial guidance for the upcoming year, largely driven by the increasing demand for its innovative anticoagulant, Eliquis, as well as the successful market introduction of several new therapeutics. The pharmaceutical giant's optimistic outlook comes at a time when the pharmaceutical landscape is highly competitive, yet Bristol Myers appears to be carving out a significant niche with its portfolio.

Breaking Down AstraZeneca's Bold $2 Billion Leap Into The Future of Cholesterol Management

3 months ago

In a strategic move set to redefine its footprint in the pharmaceutical industry, AstraZeneca has announced a monumental deal valued at $2 billion to acquire the rights to a promising cholesterol-lowering drug. This decision marks a significant evolution in AstraZeneca's portfolio as it seeks to solidify its position in the cardiovascular therapeutics market.

Pfizer’s Sickle Cell Drug Candidates Unaffected by Oxbryta Withdrawal

3 months ago

In what is a major development in the pharma space, Pfizer Inc. said that its set of upcoming sickle cell drug candidates remain unaffected by the recent withdrawal of Oxbryta, another medication pointed toward treating the same condition. An update comes amidst increased scrutiny on drug efficacy and regulatory compliance.